Author Topic: £11m Speke e-cigarette factory will create 150 jobs  (Read 1224 times)

0 Members and 1 Guest are viewing this topic.

Offline itsmeitis

  • Diamond Member
  • *******
  • Posts: 19147
  • lapsus linguae
£11m Speke e-cigarette factory will create 150 jobs
« on: December 04, 2014, 05:24:17 PM »
An £11m investment in Speke will create Europe’s biggest nicotine manufacturing site, leading to 150 jobs.

Joint venture Nerudia is a partnership between two entrepreneurs who founded one of the UK’s first electronic cigarette brands, and a global pharmaceutical nicotine supplier, German company Contraf-Nicotex-Tobacco (CNT).
David Newns and Chris Lord sold their e-cigarette business C N creative – owner of the Intellicig brand – to tobacco company BAT in 2012.
They have now linked with their German partner to form Nerudia.

The business, which is investing £11m into the new facility, will focus on the development, production, testing and regulatory compliance of nicotine products specifically for the fast-growing e-cigarette market, supplying brand owners rather than consumers.
The new venture, based on Physics Road at Southern Gateway, will occupy an 80,000 sq ft facility and will be fully operational by January 2015.
It is currently recruiting for 30 roles and expects to create up to 150 jobs in the first three years. It has also secured its first major manufacturing contract and is in advanced discussions with several other e-cigarette brands.

E-cigarettes, also known as vaporisers, have grown rapidly since their inception just over a decade ago. The global market is now estimated to be worth £1.8bn, and is growing at 70% per year.
David Newns, Nerudia chief executive, said: “A new EU Directive will come into force in 2016 creating a new and welcome regulated environment for e-cigarettes.
“Many of the requirements of the new regulation surround the ‘quality’ of e-cigarettes and their contents.
“The knowledge that we have gained over the past six years of working with the UK and other regulators enables us to offer a unique service to help companies through the process of new regulation.
“Our new facility will offer the expanding market a fully-outsourced, best-in-class nicotine product manufacturing service providing e-liquids and capsule filling, enabling e-cigarette companies to focus on their sales and marketing in this rapidly growing sector.”

He added: “The growth of the vaporiser market has been a modern phenomenon, but with that growth has come an increasing focus on key areas of product innovation quality and reliability.
“This is a fast-moving landscape and few brands can build the capabilities in-house to keep pace.
“Nerudia has been created to offer the market the very latest product innovation, manufacturing technology, testing facilities and compliance procedures, enabling brands to concentrate on what they do best.”

Torsten Siemann, managing director of CNT, said: “Nerudia is an exciting opportunity for CNT allowing us to expand our integrated supply chain further.

“In addition to the supply of ultrapure nicotine made in Switzerland, we will be able to support our customers throughout Europe in their quest to comply with the impending EU regulations that will be in force from 2016.
With Nerudia we will be in the position to offer our tobacco as well as our pharmaceutical customers access to world-class innovation and manufacturing expertise in this new and fast moving category.”

CNT is the world’s largest supplier of pharmaceutical grade nicotine and is a global operating company involved in growing, sourcing, developing, processing, extracting and producing a range of agriculturally originated products.
Headquartered in Heilbronn, Germany, it has operations in India, South America and Africa and supplies some of the world’s largest tobacco and pharmaceutical manufacturers with raw materials and processed products.

source Liverpool Echo